Tessera Therapeutics

Description

Develops Gene Writing technology and non-viral delivery methods to make targeted genome alterations for therapies addressing major unmet medical needs.

Tessera Therapeutics is located in the Boston ecosystem.

Related

• Flagship PioneeringParentBuilds life sciences companies through scientific exploration and strategic collaborations, aiming to create products for drug discovery,…
• Liquidia ($LQDA)Develops therapies and lung drug-delivery technology for rare cardiopulmonary diseases, including pulmonary arterial hypertension,…
• Prime Medicine ($PRME)Develops one-time genetic therapies using prime editing to locate genome targets and replace faulty DNA segments for patients with diseases…
• Neumora TherapeuticsDevelops treatments for brain diseases, advancing CNS-targeted medicines and precision approaches to understand disease biology and…
• BMS Cell Therapy Washington ($BMY)Develops, manufactures, and commercializes cancer immunology and cell therapies for people with difficult-to-treat cancers and other…
• Beam Therapeutics ($BEAM)Develops investigational base-editing genetic medicines and delivery technologies, including electroporation, nonviral, and viral methods,…
• Avalon BioVenturesInvests in and builds biotech companies addressing unmet medical needs, providing portfolio teams with capital, expertise, mentorship,…
• Editas Medicine ($EDIT)Develops CRISPR-based gene editing medicines, including in vivo approaches, for people with serious diseases where modifying genes may…
• Capsida BiotherapeuticsDevelops targeted genetic medicines and engineered capsids for neurological and ocular diseases, including IV-delivered CNS gene therapies…
• Dyno TherapeuticsBuilds high-performance genetic technologies to improve AAV gene delivery for gene therapy, supporting therapeutic developers working on…
• AsimovBuilds an end-to-end genetic design platform combining synthetic biology and computational tools for biologics, cell therapy, and gene…
• Verve TherapeuticsSingle-course gene-editing therapies for cardiovascular disease. Cambridge MA; CRISPR-based PCSK9 + ANGPTL3 programs.